Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues

被引:13
作者
BouchetBernet, C
Spyratos, F
Andrieu, C
Deytieux, S
Becette, V
Oglobine, J
机构
[1] CTR RENE HUGUENIN,LAB BIOL TISSULAIRE,F-92211 ST CLOUD,FRANCE
[2] CTR RENE HUGUENIN,DEPT ANATOMOCYTOPATHOL,F-92211 ST CLOUD,FRANCE
关键词
ELISA; breast cancer; plasminogen activator inhibitor-2; prognosis; urokinase receptor;
D O I
10.1007/BF01807159
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The levels of uPA, its inhibitors PAI-1 and PAI-2, and the uPA receptor (uPAR) have prognostic value in breast cancer. However, different extraction methods and assays kits are used in different laboratories and may directly influence the levels observed. To define a buffer suitable for both PAI-2 and uPAR extraction from breast cancer tissue compatible with hormone receptors and other cytosolic prognosticator assays, we compared PAI-2 and uPAR values obtained by immunoenzymatic assays (American Diagnostica, Greenwhich, USA) in several extraction conditions: 1) cytosol obtained with the standard hormone receptor buffer; 2) solubilized pellets obtained by Triton X100 extraction of the pelleted membranes obtained with standard hormone receptor buffer; 3) cytosol obtained by direct extraction in the buffer (containing Triton X100) recommended by the manufacturer, after 2 hours or 12 hours of incubation. Cytosol extracts prepared using the standard procedure recommended for hormone receptors gave the highest PAI-2 values. The highest uPAR values were obtained in the subsequent detergent extraction of the pelleted membranes. PAI-2 levels obtained with the kit manufacturer's method after 12 hours of incubation were lower than those obtained after 2 hours of incubation, whereas uPAR levels were similar. We conclude that the most suitable extraction protocol employs standard hormone receptor extraction buffer to obtain a supernatant cytosol fraction for PAI-2 assay, and subsequent detergent extraction of the pelleted membranes to obtain an extract suitable for uPAR.
引用
收藏
页码:141 / 146
页数:6
相关论文
共 18 条
  • [1] BIANCHI E, 1994, CANCER RES, V54, P861
  • [2] PROGNOSTIC VALUE OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (UPA) AND PLASMINOGEN-ACTIVATOR INHIBITORS PAI-1 AND PAI-2 IN BREAST CARCINOMAS
    BOUCHET, C
    SPYRATOS, F
    MARTIN, PM
    HACENE, K
    GENTILE, A
    OGLOBINE, J
    [J]. BRITISH JOURNAL OF CANCER, 1994, 69 (02) : 398 - 405
  • [3] DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO
  • [4] 2-B
  • [5] UROKINASE PLASMINOGEN-ACTIVATOR AND UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR IN BREAST-CANCER
    DUGGAN, C
    MAGUIRE, T
    MCDERMOTT, E
    OHIGGINS, N
    FENNELLY, JJ
    DUFFY, MJ
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) : 597 - 600
  • [6] PLASMINOGEN-ACTIVATOR INHIBITOR-1 AND PROGNOSIS IN PRIMARY BREAST-CANCER
    FOEKENS, JA
    SCHMITT, M
    VANPUTTEN, WLJ
    PETERS, HA
    KRAMER, MD
    JANICKE, F
    KLIJN, JGM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) : 1648 - 1658
  • [7] FOEKENS JA, 1995, CANCER RES, V55, P1423
  • [8] GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513
  • [9] HOLLAS W, 1991, CANCER RES, V51, P3690
  • [10] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (U-PA) ANTIGEN IS A PREDICTOR OF EARLY RELAPSE IN BREAST-CANCER
    JANICKE, F
    SCHMITT, M
    HAFTER, R
    HOLLRIEDER, A
    BABIC, R
    ULM, K
    GOSSNER, W
    GRAEFF, H
    [J]. FIBRINOLYSIS, 1990, 4 (02) : 69 - 78